A systematic overview of chemotherapy effects in breast cancer.
about
Current treatment of early breast cancer: adjuvant and neoadjuvant therapyHigh expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth?siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cellsCurrent status of the prognostic molecular biomarkers in breast cancer: A systematic reviewAdjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival.Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Breast cancer, sickness absence, income and marital status. A study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosisAntitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.Combination chemotherapy for metastatic breast cancer.Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhA systematic overview of radiation therapy effects in breast cancer.Ophthalmic Metastasis of Breast Cancer and Ocular Side Effects from Breast Cancer Treatment and Management: Mini ReviewEverolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician surveyHow Effective is the Treatment of Locally Advanced and Metastatic Breast Cancer in Developing Centres?: A Retrospective Review.Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesionsOestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancerEnhancing the Effects of Low Dose Doxorubicin Treatment by the Radiation in T47D and SKBR3 Breast Cancer Cells.Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy.Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.Maintenance treatment in metastatic breast cancer.Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk.Transplantation of female genital organs.Local therapy and survival in breast cancer with distant metastases.Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.Symptom distress, functional status and health-related quality of life before high-dose chemotherapy with stem-cell transplantation.Stress degradation studies and development of stability-indicating TLC-densitometry method for determination of prednisolone acetate and chloramphenicol in their individual and combined pharmaceutical formulations.Capecitabine for the oral treatment of metastatic breast cancer.Early assessment of neoadjuvant chemotherapy by FEC-courses of locally advanced breast cancer using 99mTc-MIBI.The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer.Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.Recombinant nanocomposites by the clinical drugs of Abraxane® and Herceptin® as sequentially dual-targeting therapeutics for breast cancer.Selection of patients may limit the generalizability of results from cancer trials.Comment on: A rare case of unilateral diffuse melanocytic proliferation
P2860
Q27011658-5C2B03D5-2E0D-4FDC-B767-9F1F9BCF7F02Q27851775-34B37A50-8C89-4A8E-827E-7535C1A4BD62Q28661521-B8A19823-9168-4960-B7F4-092746CC4C93Q33439232-B7A6DA25-D624-444B-AB8A-9AEEA066058BQ33598494-D3AC7DB2-AFB1-4F78-BA10-48DB6580AC32Q33645931-62ACC9D1-3DCD-4046-91F3-2CECA50B2A47Q33749066-5A7EACC9-92B2-4D20-9093-10C2A88132FCQ33867361-51EF01E8-A87F-402A-8270-89D24A25C53CQ34528291-2E7DDB3E-1DC6-4E18-96E3-E5D722CF70F7Q34734518-F0E88586-447F-4767-B98A-6400E9864D55Q35001420-D11E41A8-E42F-447A-BDD0-A12184A15CBDQ35574871-E197CFAE-94D7-4670-9111-CB9D4B5E4AC4Q35640600-645AC999-2D91-4149-B31C-F7034A0CC7A6Q35675851-7F23CBE6-0B91-41AC-85AD-A44FD3C639FBQ36366093-147A17CD-B1F0-478B-BA38-CFDF882C03A0Q36528355-4EDB4C76-E7CF-433C-9FB3-A42DCD6000C5Q36605309-3A79C8E8-9A3B-4E2F-9180-D656C396B2DCQ36627805-8DE2493F-969A-4247-B3C9-D5C440541B73Q36670973-3AC15ADD-F498-479A-8B00-338855965BCDQ36998118-7362F11D-5652-4860-873B-4D6919F63195Q37228097-3A5C7FE8-D9C7-4471-992E-6F7C440D607FQ37332275-C68E83F3-D7E1-4B2F-B8B2-125F4867AAC5Q37338245-5E637B7D-FAEE-4465-A03B-03E550458D72Q37504993-9BCA9EE8-654C-4668-83FC-51BF0F8E7439Q37846883-37BA22C1-02EE-49EA-9963-04C8D274A463Q37914092-DD1806CC-B1A8-476F-9709-5F904652EC9EQ38930537-7725E291-4F89-43A7-8D8D-5894758B19EAQ40563373-F7B6669E-2FD9-47FA-A47C-1677B7E1D021Q42138444-9299A0AD-5687-4C1B-9E88-C8CA94619ACFQ43267032-6C3FD026-4C06-4BF3-94A7-0574C4F2890FQ44444212-E6D13D07-D735-4A13-8363-95FFE5FDB603Q46027938-A9854A65-8C9E-49C7-9882-2AB9932BD2E6Q46226343-2E2D8693-42ED-49F1-B0D6-F8352E91A012Q46727663-7BBE8707-6D57-4469-BDE0-06797C0B3977Q46755119-F6ED1390-15F5-4C75-8B24-1511E3836CEFQ49743645-73745DBD-D9D2-4AAF-9C74-7D0D8D5512E8Q50333939-3FF73198-E7BF-4F43-8C16-883BD1BB0879Q52941012-E0DA44B1-A09F-4C8D-AB48-AEB535A042C4Q58806243-4080863F-3488-4D1B-9F68-F9A0F7852E8E
P2860
A systematic overview of chemotherapy effects in breast cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A systematic overview of chemotherapy effects in breast cancer.
@ast
A systematic overview of chemotherapy effects in breast cancer.
@en
A systematic overview of chemotherapy effects in breast cancer.
@nl
type
label
A systematic overview of chemotherapy effects in breast cancer.
@ast
A systematic overview of chemotherapy effects in breast cancer.
@en
A systematic overview of chemotherapy effects in breast cancer.
@nl
prefLabel
A systematic overview of chemotherapy effects in breast cancer.
@ast
A systematic overview of chemotherapy effects in breast cancer.
@en
A systematic overview of chemotherapy effects in breast cancer.
@nl
P2093
P1433
P1476
A systematic overview of chemotherapy effects in breast cancer.
@en
P2093
P E Jönsson
SBU-group. Swedish Council of Technology Assessment in Health Care
P304
P356
10.1080/02841860151116349
P577
2001-01-01T00:00:00Z